Last €29.26 EUR
Change Today -0.015 / -0.05%
Volume 140.0
MYD On Other Exchanges
Symbol
Exchange
Frankfurt
As of 9:24 AM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

320 Wakara Way

Salt Lake City, UT 84108

United States

Phone: 801-584-3600

Fax: 801-584-3640

Myriad Genetics, Inc., a molecular diagnostic company, is engaged in the discovery and commercialization of novel, transformative tests across major diseases. The company offers 13 commercial molecular diagnostic tests, including 7 predictive medicine tests, 3 personalized medicine tests, 2 prognostic medicine tests, and 1 diagnostic medicine test. It markets these tests in the United States through its own sales force of approximately 470. The company markets its products through its own sales force in Europe and Canada, and has distributor agreements with organizations in selected Latin American, the Middle Eastern, the Asian, and the African countries. It provides pharmaceutical and clinical services to the pharmaceutical and biotechnology industries, and medical research institutions. Molecular Diagnostic Testing The company’s molecular diagnostic tests are designed to analyze genes; diagnose disease, their expression levels and proteins to assess an individual’s risk for developing disease later in life; determine a patient’s likelihood of responding to a particular drug; and assess a patient’s risk of disease progression and disease recurrence. Its commercial molecular diagnostic tests are: BRACAnalysis: A predictive medicine test for hereditary breast and ovarian cancer. The company’s BRACAnalysis test is an analysis of the BRCA1 and BRCA2 genes for assessing a woman’s risk of developing hereditary breast and ovarian cancer. Additionally, BRACAnalysis might used to assist patients already diagnosed with breast or ovarian cancer and their physicians in determining the appropriate therapeutic interventions to address their disease. BART: A predictive medicine test for hereditary breast and ovarian cancer. The company’s BART test is based on proprietary technology for detecting genomic rearrangements in the genes involved in hereditary breast and ovarian cancer patients. BART might be used to identify these mutation carriers. COLARIS: A predictive medicine test for hereditary colorectal and uterine cancer. The company’s COLARIS test is an analysis of the MLH1, MSH2, MSH6, PMS2, EPCAM, and MYH genes for assessing a person’s risk of developing colorectal and uterine cancer. Colon cancer is a preventable disease if high-risk individuals diligently have colonoscopies and remove any precancerous polyps. COLARIS AP: A predictive medicine test for hereditary colorectal cancer. The company’s COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome, such as familial adenomatous polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (Multi-Analyte Profile (MAP)). Effective preventive measures include colonoscopy and the removal of pre-cancerous polyps and prophylactic surgery. EndoPredict: A personalized medicine test for breast cancer. The company’s EndoPredic test is a next generation RNA expression test used to determine which women with breast cancer would benefit from chemotherapy. EndoPredict detects the likelihood of late metastases, metastases occurring after five years, to guide treatment decisions for chemotherapy and extended anti-hormonal therapy. EndoPredict has been shown to predict cancer-specific disease progression and metastases with no confusing intermediate results in 13 published clinical studies with approximately 2,200 patients and is CE marked. MELARIS: A predictive medicine test for hereditary melanoma. The company’s MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. Individuals who test positive with a MELARIS test have a 75-fold increased risk of developing melanoma during their lifetimes as compared to the general population. Melanoma might be prevented through appropriate screening and a specific threshold of action for mutation carriers in which pre-cancerous lesions are removed before cancer could develop. myPath Melanoma: A diagnostic medicine test for melanoma. The company’s myPath Melanoma test is a gene expression based profile that is performed on biopsy tissue for the purpose of aiding a derma

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYD:GR €29.26 EUR -0.015

MYD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Drainage Systems Inc $19.68 USD -0.27
Bio-Reference Laboratories Inc $28.05 USD -0.1999
Foundation Medicine Inc $20.00 USD -0.0899
Genomic Health Inc $29.49 USD +0.005
Imperial Innovations Group PLC 470.00 GBp +5.00
View Industry Companies
 

Industry Analysis

MYD

Industry Average

Valuation MYD Industry Range
Price/Earnings 16.6x
Price/Sales 3.6x
Price/Book 3.8x
Price/Cash Flow 15.5x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.